Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma
NCT04955886Phase 2Unknown
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Aug 2021
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in nasopharyngeal carcinoma (NPC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective Response Rate at 12 months. Status: unknown.
02
Drugs
surufatinib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04955886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955886.